Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Leases: 2021-2025

Historic Current Leases for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Sep 2025 value amounting to $5.7 million.

  • 4D Molecular Therapeutics' Current Leases rose 11.86% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 11.86%. This contributed to the annual value of $5.6 million for FY2024, which is 79.01% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Current Leases is $5.7 million, which was down 0.45% from $5.7 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Current Leases high stood at $5.7 million for Q2 2025, and its period low was $1.2 million during Q4 2021.
  • For the 3-year period, 4D Molecular Therapeutics' Current Leases averaged around $4.2 million, with its median value being $3.2 million (2024).
  • Data for 4D Molecular Therapeutics' Current Leases shows a peak YoY surged of 115.68% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Current Leases stood at $1.2 million in 2021, then skyrocketed by 115.68% to $2.7 million in 2022, then rose by 18.61% to $3.1 million in 2023, then surged by 79.01% to $5.6 million in 2024, then increased by 11.86% to $5.7 million in 2025.
  • Its Current Leases was $5.7 million in Q3 2025, compared to $5.7 million in Q2 2025 and $5.7 million in Q1 2025.